SC
AZN icon

SummitTX Capital’s AstraZeneca AZN Stock Holding History

SummitTX Capital’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-59,970
Closed -$11M – 771
2025
Q4 		$11M Buy
59,970
+35,159
+142% +$6.17M 0.33% 63
2025
Q3 		$3.81M Buy
24,811
+20,980
+548% +$3.18M 0.16% 144
2025
Q2 		$535K Buy
+3,831
New +$537K 0.02% 498

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

SummitTX Capital's AZN Position: Q1 2026 in Review

SummitTX Capital sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 59,970 shares — an estimated $11M sold.

SummitTX Capital first reported a position in AZN in Q2 2025 and held it in 3 quarters. The position peaked at $11M in Q4 2025. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • SummitTX Capital reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
  • SummitTX Capital sold 59,970 AstraZeneca shares in Q1 2026, an estimated $11M.
  • SummitTX Capital first reported a position in AstraZeneca in Q2 2025 and held it in 3 quarters.
  • SummitTX Capital's AstraZeneca position peaked at $11M in Q4 2025.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on SummitTX Capital's 13F filing for Q1 2026, filed 15 May 2026.